[Hemorheological, hemocoagulation and photoplethysmographic changes induced by the administration of pentoxifylline in patients with Raynaud's disease].
1200 mg/day per os of Pentoxyphyllin administered for 60 day brought about an improvement in symptomatology and photoplethysmographic readouts under base conditions and following the cooling test in 7 out of 11 females suffering from Raynaud's disease. These results may be explained by an improved microcirculation flow resulting from increased erythrocyte filterability and a decrease in fibrinogenemia .
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D005260:Female; D006801:Humans; D008833:Microcirculation / Q000187:drug effects*; D010431:Pentoxifylline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010991:Plethysmography; D011928:Raynaud Disease / Q000097:blood / Q000188:drug therapy*; D013805:Theobromine / Q000031:analogs & derivatives*
D013805:Theobromine; D010431:Pentoxifylline
Modificazioni emoreologiche, emocoagulative e fotopletismografiche indotte dalla somministrazione di pentossifillina in soggetti con malattia di Raynaud.